Skip to main content
. 2021 Jul 28;40(5):299–309. doi: 10.1016/j.remnie.2021.07.005

Figure 5.

Figure 5

(A) 18F-FDG PET/CT study in a patient who had received the first dose of Vaxzevria 5 days previously. The MIP image shows focal uptake in the area of the injection site in the left arm and ipsilateral axillary adenopathies localized at levels I and II in the axial CT and PET/CT slices.

(B) 68Ga-edotreotide (Somakit-TOC) PET/CT study in a patient who had received the second dose of Vaxzevria 15 days previously. The MIP image shows uptake in the left axilla corresponding to adenopathies at the left axillary level I, visible in the axialCT and PET/CT slices.